Biocon Limited
BIOCON.NS
₹402.20
▲ 0.30%
Biocon inched up 0.30% to Rs 402.20 in a session devoid of any company-specific news. The biopharma major's longer-term returns have been fairly muted, with a 5-year CAGR of just 2.04% and a 10-year CAGR of 10.11%, though the past year has seen a somewhat better showing at 11.24%. Twenty analysts covering the stock have settled on a hold consensus, with an average target price of Rs 439.05 sitting above the current market price.
CAGR Performance
| 1 Year | 2 Years | 5 Years | 10 Years |
|---|---|---|---|
| 12.26% | 2.76% | 1.96% | 10.06% |
Analyst Consensus
Average Target Price: ₹439.05 (range ₹290.00 - ₹534.00) based on 20 analysts
Strong Buy: 1
Buy: 8
Hold: 3
Sell: 2
Strong Sell: 5
Related News
| Aug 18, 2026 | Biocon Announces U.S. FDA Approval For Yesintek Single-Dose Prefilled Autoinjector |
| Aug 13, 2026 | Biocon Limited Share Price Falls 2.55% Today (Aug 13, 2026) |
No comments:
Post a Comment